Status:
COMPLETED
Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Diabetes Mellitus
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.
Eligibility Criteria
Inclusion
- Men or women, aged 18 to 55 years
- Body mass index in the range of 18 to 30 kg/m2
- Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead ECG
Exclusion
- History of cardiac, thyroid, muscle, or kidney abnormalities
- A family history of long QT syndrome and/or sudden cardiac death
- History of any clinically significant drug allergy, hypersensitivity to sulfonomides or the quinolone class of antibiotics
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
End Date :
March 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00447629
Start Date
January 1 2007
End Date
March 1 2007
Last Update
December 5 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85044